Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer

NCT01505413 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Erlotinib
DRUG: Gemcitabine
DRUG: Oxaliplatin

Sponsor

Soonchunhyang University Hospital